Responses
Other responses
Jump to comment:
- Published on: 9 January 2022
- Published on: 9 January 2022
- Published on: 9 January 2022Comment on Lack of efficacy of rituximab in refractory wegener's granulomatosisShow More
Dear Editor
Aries et al. demonstrate in their study, the lack of response of granulomatous disease in Wegener's granulomatosis to rituximab. From my reading of the paper, this agent was given every fourth week. This is not how this agent is usually prescribed, ie usually given as weekly pulses for four weeks. Despite this, Bcell numbers were depleted in the peripheral blood, though I would doubt at this low dose...
Conflict of Interest:
None declared. - Published on: 9 January 2022Rituximab treatment in Wegener's GranulomatosisShow More
Dear Editor,
We read the article by Aries and colleagues with great interest. The authors describe a cohort of 8 patients with refractory Wegener’s granulomatosis, of which 6 had no apparent response to Rituximab. Based on this lack of response and based on the clinical disease manifestations of the patients, the authors conclude that Rituximab may be ineffective in patients with refractory granulomatous disease ma...
Conflict of Interest:
None declared.